• Increase Font

    Triple directing-acting combination treats decompensated liver disease

    A combination of simeprevir, sofosbuvir and daclatasvir has the potential to become a short-duration, ribavirin-free alternative regimen for the treatment of difficult-to-cure hepatitis C virus (HCV) GT1-infected patients, according to a new study.

    “HCV treatment continues to improve. High sustained virologic response (SVR) rates can be achieved even in patents with very advanced disease and other characteristics historically associated with poor treatment outcomes,” Eric Lawitz, MD, clinical professor of medicine at the University of Texas Health Science Center in San Antonio, Texas, told Medical Economics.

    The researchers published their in the April 2017 Journal of Viral Hepatitis.

    Chronic HCV infection is associated with the development of cirrhosis, and patients who develop decompensated cirrhosis have decreased survival rates compared with those who have compensated cirrhosis. Despite availability of treatment for HCV infection in patients with decompensated liver disease, treatment options must be carefully considered in this patient group due to the severity of their underlying disease, said Lawitz.

    Next: Study details

    Mark L. Fuerst
    Staff Correspondent

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow